Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug

Brain Research

Volumn 1111, Issue 1, 2006, Pages 72-82

  Camarasa, Jordi ^a   Pubill, David ^a   Escubedo, Elena ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antinociception; Caffeine; MDMA; Neurotoxicity; Rat

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CAFFEINE; RECREATIONAL DRUG; SEROTONIN 2 RECEPTOR;

ADOLESCENT; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BODY TEMPERATURE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG POTENTIATION; HIPPOCAMPUS; HYPERTHERMIA; LOCOMOTION; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION;

ANALGESICS; ANIMALS; BODY TEMPERATURE; BRAIN; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG INTERACTIONS; FEVER; HALLUCINOGENS; MALE; MICE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTOXINS; PAIN; PRESYNAPTIC TERMINALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 33748313455     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.06.087     Document Type: Article

References (44)

1. Battaglia G., Yeh S.Y., O'Hearn E., Molliver M.E., Kuhar M.J., and De Souza E.B. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242 (1987) 911-916
2. Battaglia G., Yeh S.Y., and De Souza E.B. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 29 (1988) 269-274
3. Cadoni C., Solinas M., Pisanu A., Zernig G., Acquas E., and Di Chiara G. Effect of 3,4-methylendioxymethamphetamine (MDMA, "ecstasy") on dopamine transmission in the nucleus accumbens shell and core. Brain Res. 1055 (2005) 143-148
4. Colado M.I., O'Shea E., and Green AR. Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berlin) 173 (2004) 249-263
5. Conductier G., Crosson C., Hen R., Bockaert J., and Compan V. 3,4-N-methlenedioxymethamphetamine-induced hypophagia is maintained in 5-HT1B receptor knockout mice, but suppressed by the 5-HT2C receptor antagonist RS102221. Neuropsychopharmacology 30 (2005) 1056-1063
6. Crisp T., Stafinsky J.L., Boja J.W., and Schechter M.D. The antinociceptive effects of 3,4-methylenedioxymethamphetamine (MDMA) in the rat. Pharmacol. Biochem. Behav. 34 (1989) 497-501
7. Escubedo E., Guitart L., Sureda F.X., Jimenez A., Pubill D., Pallas M., Camins A., and Camarasa J. Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res. 814 (1998) 120-126
8. Ferre S., Fuxe K., von Euler G., Johansson B., and Fredholm B.B. Adenosine-dopamine interactions in the brain. Neuroscience 51 (1992) 501-512
9. Fredholm B.B., Bättig K.C., Holmen J.A., Nehlig A.D., and Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51 (1999) 83-133
10. Ghelardini C., Galeotti N., and Bartolini A. Caffeine induces central cholinergic analgesia. Naunyn-Schmiedeberg's Arch. Pharmacol. 356 (1997) 590-595
11. Godfrey L., Yan L., Clarke G.D., Ledent C., Kitchen I., and Hourani S.M. Modulation of paracetamol antinociception by caffeine and by selective adenosine A(2) receptor antagonists in mice. Eur. J. Pharmacol. 531 (2006) 80-86
12. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55 (2003) 463-508
13. Gudelsky G.A., and Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem. 66 (1996) 243-249
14. Kehne J.H., Ketteler H.J., McCloskey T.C., Sullivan C.K., Dudley M.W., and Schmidt C.J. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 15 (1996) 116-124
15. Kim D.S., and Palmiter R.D. Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1346-1351
16. Klingler W., Heffron J.J., Jurkat-Rott K., O'sullivan G., Alt A., Schlesinger F., Bufler J., and Lehmann-Horn F. 3,4-Methylenedioxymethamphetamine (ecstasy) activates skeletal muscle nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 314 (2005) 1267-1273
17. Koster R., Anderson M., and de Beer E.J. Acetic acid for analgesic screening. Fred. Proc. 18 (1959) 412
18. Laska E.M., Sunshine A., Mueller F., Elvers W.B., Siegel C., and Rubin A. Caffeine as an analgesic adjuvant. J. Am. Med. Assoc. 251 (1984) 1711-1718
19. Le Donne K.T., and Sonsalla P.K. Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J. Pharmacol. Exp. Ther. 271 (1994) 1320-1326
20. McCreary A.C., Bankson M.G., and Cunningham K.A. Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors. J. Pharmacol. Exp. Ther. 290 (1999) 965-973
21. McGuire P.K., Cope H., and Fahy T.A. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('Ecstasy'). Br. J. Psychiatr. 165 (1994) 391-395
22. McNamara R., Kerans A., O'Neill B., and Harkin A. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love"). Neuropharmacology 50 (2006) 69-80
23. O'Callaghan J.P., and Holtzman S.G. Prenatal administration of morphine to the rat: tolerance to the analgesic effect of morphine in the offspring. J. Pharmacol. Exp. Ther. 197 (1976) 533-544
24. O'Loinsigh E.D., Boland G., Kelly J.P., and O'Boyle K.M. Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 25 (2001) 621-638
25. O'Regan M.C., and Clow A. Decreased pain tolerance and mood in recreational users of MDMA. Psychopharmacology (Berlin) 173 (2004) 446-451
26. Okada M., Kiryu K., Kawata Y., Mizuno K., Wada K., Tasaki H., and Kaneko S. Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. Eur. J. Pharmacol. 321 (1997) 181-188
27. Powell K.R., Iuvone P.M., and Holtzman S.G. The role of dopamine in the locomotor stimulant effects and tolerance to these effects of caffeine. Pharmacol. Biochem. Behav. 69 (2001) 59-70
28. Pubill D., Canudas A.M., Pallas M., Camins A., Camarasa J., and Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn-Schmiedeberg's Arch. Pharmacol. 367 (2003) 490-499
29. Rempel N.L., Callaway C.W., and Geyer M.A. Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology 8 (1993) 201-211
30. Reneman L., Endert E., De B.K., Lavalaye J., Feenstra M.G., de Wolff F.A., and Booij J. The acute and chronic effects of MDMA ("ecstasy") on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 26 (2002) 387-396
31. Saadat K.S., O'Shea E., Colado M.I., Elliott J.M., and Green A.R. The role of 5-HT in the impairment of thermoregulation observed in rats administered MDMA ('ecstasy') when housed at high ambient temperature. Psychopharmacology (Berlin) 179 (2005) 884-890
32. Scheffel U., Lever J.R., Stathis M., and Ricaurte G.A. Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors. Neuropharmacology 31 (1992) 881-883
33. Schmidt C.J., Levin J.A., and Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem. Pharmacol. 36 (1987) 747-755
34. Schmidt C.J., Fadayel G.M., Sullivan C.K., and Taylor V.L. 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 223 (1992) 65-74
35. Shankaran M., and Gudelsky G.A. Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol. Biochem. Behav. 61 (1998) 361-366
36. Shibata M., Ohkubo T., Takahashi H., and Inoki R. Modified formalin test: characteristic biphasic pain response. Pain 38 (1989) 347-352
37. Sprague J.E., and Nichols D.E. The monoamine oxidase-B inhibitor l-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 273 (1995) 667-673
38. Sprague J.E., Everman S.L., and Nichols D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19 (1998) 427-441
39. Steele T.D., Nichols D.E., and Yim G.K. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem. Pharmacol. 36 (1987) 2297-2303
40. Sveen M.L., Knudsen G.M., and Aznar S. No effect of MDMA (ecstasy) on cell death and 5-HT2A receptor density in organotypic rat hippocampal cultures. Neurosci. Lett. 362 (2004) 6-9
41. Wallace T.L., Gudelsky G.A., and Vorhees C.V. Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoamine-depleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine. Psychopharmacology (Berlin) 153 (2001) 321-326
42. Wang Q.P., and Nakai Y. The dorsal raphe: an important nucleus in pain modulation. Brain Res. Bull. 34 (1994) 575-585
43. White S.R., Duffy P., and Kalivas P.W. Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo. Neuroscience 62 (1994) 41-50
44. Yamamoto B.K., Nash J.F., and Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther. 273 (1995) 1063-1070